First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat

BACKGROUND: Vafidemstat, an inhibitor of the histone lysine-specific demethylase KDM1A, corrects cognition deficits and behavior alterations in rodent models. Here, we report the results from the first-in-human trial of vafidemstat in healthy young and older adult volunteers. A total of 110 voluntee...

Descripción completa

Detalles Bibliográficos
Autores principales: Antonijoan, Rosa María, Ferrero-Cafiero, Juan Manuel, Coimbra, Jimena, Puntes, Montse, Martínez-Colomer, Joan, Arévalo, María Isabel, Mascaró, Cristina, Molinero, Cesar, Buesa, Carlos, Maes, Tamara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985749/
https://www.ncbi.nlm.nih.gov/pubmed/33755924
http://dx.doi.org/10.1007/s40263-021-00797-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985749/
https://www.ncbi.nlm.nih.gov/pubmed/33755924
http://dx.doi.org/10.1007/s40263-021-00797-x

Ejemplares similares